

TriHealth Cancer Institute's Collaboration with the Tempus AI TIME Program Impact on Clinical Trial Operations and Enrollment




James Maher¹, Samantha Mallahan², Jason J. Claes¹, Wayne Thompson¹, Benjamin Kuritzky¹, Robert Neff¹, Seerin Shatavi¹, Courtney Rice¹, Karen Huelsman¹, Leanne Budde¹, Faisal Adhami¹, Megan Shulman², Meg Degele², Blathnaid Donovan², Danielle Skelly², Emily Patnaude², Christian Clifford², Annie Darmofal², Chelsea Osterman², Matthew Cooney²

²Tempus AI, Inc., Chicago, IL, ¹TriHealth Cancer and Blood Institute, Cincinnati, OH

INTRODUCTION

TriHealth Cancer & Blood Institute, the largest personalized medicine program servicing Cincinnati, partnered with Tempus AI TIME program to improve patient recruitment and enrollment in oncology clinical trials over a 15 month period.

Figure 1. TIME Program



SUMMARY & CONCLUSIONS

TIME Program enhanced patient identification and enrollment in oncology clinical trials for TriHealth Cancer & Blood Institute

- **18,800+** patients screened for **135** trials using AI enabled algorithmic patient matching software (TApp) over 15 months
- **8.6M** unique TApp searches resulted in **1,900+** patients screened by Tempus RNs, **284** matches, and **28** consents
- **2.3X increase** in trial activations and **80% reduction** in days to activate
- **9.3 fold** increase in enrollment in TIME trials compared to non-TIME studies

RESULTS

Table 1. TIME Matching, Screening, & Enrollment Outcomes

Quarter	TApp Searches	Reviewed by Tempus RN	Passed Tempus RN Review	Consents	Trial Activations
Q1 2022	427,381	74	27	0	0
Q2 2022	521,772	144	75	2	4
Q3 2022	1,416,863	200	78	10	1
Q4 2022	2,637,428	249	57	10	1
Q1 2023	3,649,953	1277	47	6	1
Total	8,653,397	1944	284	28	7

Table 2. TIME vs non-TIME Trial Activations

TIME or non-TIME Trial	Number of Activations	Average Business Days to Activate	Median Business Days to Activate	Enrollments
TIME	7	37	28	28
non-TIME	3	186	183	3

Table 3. Trial Portfolio Insights by Cancer Type, Phase, & Biomarkers

Cancer Type	% of Trial Portfolio	Phase	% of Trial Portfolio	Most Common Biomarkers
Non-Small Cell Lung	26.1%	Phase I	22.3%	EGFR NTRK KRAS HER2 BRAF ROS1 PIK3CA ER
Solid Tumor	18.5%	Phase I & II	18.1%	
Heme	11.8%	Phase II	26.6%	
Breast	8.4%	Phase III	28.7%	
Colorectal	5.0%	Other (Phase IV, II & III)	4.3%	

METHODS

Figure 2. TIME Program Workflow






Figure 3. TApp Screening



FUTURE STEPS



ACKNOWLEDGMENTS

We thank Amrita A. Iyer, Ph.D from the Scientific Communications team at Tempus for poster development and review.

Correspondence: matthew.cooneyl@tempus.com